Elanco Animal Health Incorporated (ELAN) Stock

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated is led by CEO Jeffrey N. Simmons, employs 9,900 people, headquartered in Indianapolis, US, publicly traded since 2018.

Elanco Animal Health Incorporated (ELAN) stock trades at $22.52 with a market capitalization of $11.25B. The stock is valued at a negative price-to-earnings (P/E) ratio of -54.00, reflecting a net loss over the last twelve months, price-to-book of 1.68, price-to-sales of 2.20. Over the past 52 weeks the stock has ranged between $19.40 and $27.98, and currently trades 19.5% below its 52-week high.

On profitability, Elanco Animal Health Incorporated generates a return on equity (ROE) of -3.02% (negative, reflecting a net loss), return on capital employed of 3.95%, an operating margin of 5.34%, a net profit margin of -3.96%.

Elanco Animal Health Incorporated by the numbers, 2016–2025

Between 2016 and 2025 Elanco Animal Health Incorporated reported revenue of $2.9B rising to $4.7B, a change of +61.8% across 10 years. Compounded, revenue has grown 7.6% a year over five years, 2.3% over three, 6.2% over the last twelve months. Net profit fell to $-232.0M.

Operating margin went from 9.7% in 2016 to 5.3% in 2025, a fall of 4.4 percentage points. The most recent net margin is -3.96%. On a trailing twelve-month basis to Jun '26, revenue is $5.0B and net profit $-199.0M.

Borrowings stand at $4.0B, cash from operations was $560.0M in the latest year, positive in 9 of the last 10.

Return on equity has averaged -5.1% over five years, and was -3.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Elanco Animal Health Incorporated (ELAN) — frequently asked questions